The genito-urinary drugs market consists of sales of genito-urinary drugs and related services by entities (organizations, sole traders and partnerships) that produce genito-urinary drugs to treat genito- urinary diseases. This industry includes establishments that produce infertility drugs, hormonal contraceptives, erectile dysfunction drugs and hormonal replacement drugs to treat infertility, infections and prevent pregnancy. It also consists of establishments which produce drugs for benign prostatic hypertrophy, drugs for urinary incontinence and overactive bladder, diuretics to treat urinary calculi, cystic kidney disease, Reno vascular diseases, glomerular disorders and other urinary disorders.
The global genito-urinary drugs market is expected to decline from $54.2 billion in 2019 to $43.8 billion in 2020 at a compound annual growth rate (CAGR) of -19.3%. The decline is mainly due to the disruption caused by the lockdown measure across various countries to contain COVID-19 spread. Currently there is less demand for genito-urinary drugs mainly as people are staying at home and are less likely to get exposed to factors that might cause genito-urinary infections, or other hormonal diseases caused by lifestyle changes or eating habits. The market is then expected to recover and grow at a CAGR of 4% from 2021 and reach $61.4 billion in 2023.
